Search - tctmd.com

Displaying 581 - 600 of 664

Sort: Relevancy | Date

Presentation THT 2022

Novel Drug Therapies for HCM

Presenter: Carolyn Ho

February 01, 2022

Presentation THT 2022

Results From First-In-Human Clinical Trial of RP-A501 (AAV9:LAMP2B) Gene Therapy Treatment for Danon Disease

Presenter: Barry Greenberg

February 01, 2022

Presentation THT 2022

How to Make the Diagnosis

Presenter: Parag Goyal

February 01, 2022

Presentation THT 2022

The Role of Genetic Testing in Heart Failure (When Should You Order It)

Presenter: W. H. Wilson Tang

February 01, 2022

Presentation THT 2022

The Underlying Pathophysiology

Presenter: Greg Lewis

February 01, 2022

Presentation THT 2022

PROTECT IV: A Transcatheter Heart Failure Therapy Trial

Presenter: Gregg Stone

February 01, 2022

Presentation THT 2022

Current status of the REBALANCE-HF US FDA randomized feasibility clinical trial in HFpEF

Presenter: Sanjiv Shah

February 01, 2022

Presentation THT 2022

Long-term follow-up on FIH experience using the Satera Ablation System in HFpEF and HFrEF

Presenter: Sanjiv Shah

February 01, 2022

Presentation THT 2022

Evidence for Revascularization in HFrEF Patients

Presenter: Kathleen Kearney

February 01, 2022

Presentation THT 2022

CAD and HFrEF: Mind the Gap

Presenter: Adam DeVore

February 01, 2022

Presentation THT 2022

Overview of the physiology of the splanchnic bed in HFpEF and HFrEF

Presenter: Marat Fudim

February 01, 2022

Presentation THT 2022

AMI vs HF-Shock: They Are NOT the Same

Presenter: Navin Kapur

February 01, 2022

Presentation THT 2022

Interstitial Space Fluid / Lymphatics

Presenter: Maxim Itkin

February 01, 2022

Presentation THT 2022

DCD - Donation After Cadiac Death

Presenter: Nader Moazami

February 01, 2022

Presentation THT 2022

Recovered EF Heart Failure -- Physiology, Clinical Implications, and Treatment

Presenter: Douglas Mann

February 01, 2022

Presentation THT 2022

Featured Lecture: How to Incorporate New Therapies and In What Order -- Ahead of the Guidelines

Presenter: Milton Packer

February 01, 2022

Presentation THT 2022

Omecamtiv Mecarbil - Is It More Effective in Low EFs

Presenter: John Teerlink

February 01, 2022

Presentation THT 2022

Secubitirl-Valsartan Across the Spectrum of EFs

Presenter: Scott Solomon

February 01, 2022

Presentation THT 2022

Vericiguat

Presenter: Javed Butler

February 01, 2022

Presentation THT 2022

SGLT2 Inhibitors: What the Clinician Should Know

Presenter: Stefan Anker

February 01, 2022

Advertisement

Novel Drug Therapies for HCM

Results From First-In-Human Clinical Trial of RP-A501 (AAV9:LAMP2B) Gene Therapy Treatment for Danon Disease

How to Make the Diagnosis

The Role of Genetic Testing in Heart Failure (When Should You Order It)

The Underlying Pathophysiology

PROTECT IV: A Transcatheter Heart Failure Therapy Trial

Current status of the REBALANCE-HF US FDA randomized feasibility clinical trial in HFpEF

Long-term follow-up on FIH experience using the Satera Ablation System in HFpEF and HFrEF

Evidence for Revascularization in HFrEF Patients

CAD and HFrEF: Mind the Gap

Overview of the physiology of the splanchnic bed in HFpEF and HFrEF

AMI vs HF-Shock: They Are NOT the Same

Interstitial Space Fluid / Lymphatics

DCD - Donation After Cadiac Death

Recovered EF Heart Failure -- Physiology, Clinical Implications, and Treatment

Featured Lecture: How to Incorporate New Therapies and In What Order -- Ahead of the Guidelines

Omecamtiv Mecarbil - Is It More Effective in Low EFs

Secubitirl-Valsartan Across the Spectrum of EFs

Vericiguat

SGLT2 Inhibitors: What the Clinician Should Know

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content